



MicroAnalytica in partnership with BioGX are part of the fight against COVID 19

Ahead of global vaccination efforts, patient testing and social distancing measures mandated by world governments, have proven to be the only way to stem transmission rates of COVID 19.

MicroAnalytica supports the mass screening and patient testing campaign president Cyril Ramaphosa announced on 30 March 2020, by supplying Southern Africa's foremost pathology laboratories with high volume, multi-platform CE-IVD marked COVID 19 kits.

The BioGX SARS-CoV-2 HMP - N1, N2 & RNase P Multiplex is a real-time reverse transcriptase, polymerase chain reaction (PCR) assay for use on the BD MAXTM, Bio-Rad CFX96 Touch and Applied Biosystems QuantStudio 5 platforms for the qualitative detection of the presence of RNA from nucleocapsid phosphoprotein gene (N gene) of the SARS-CoV-2 coronavirus and the human RNase P gene.

The primer and probe sets are based on the United States Centres for Disease Control and Prevention (US CDC) assay for specific detection of SARS CoV-2 by amplifying two unique regions of the N gene (i.e., N1 and N2). Detection of the human RNase P gene serves as an endogenous Sample Processing Control (SPC).

We chose the N1 & N2 regions of the N gene because these are highly specific for SARS-CoV-2 and the only common gene targets both the Centres for Disease Control and the World Health Organisation agree upon. The E gene is not SARS-CoV-2 specific.

With test volumes far exceeding 100,000 the government is still stepping up ability for testing in South Africa.

MicroAnalytica in partnership with BioGX are proud to be part of the fight to test for and quarantine COVID 19.